Literature DB >> 19891874

Hepatitis C seroprevalence and associated risk factors, Anyang, China.

Fangfang Liu1, Ke Chen, Zhonghu He, Tao Ning, Yaqi Pan, Hong Cai, Yang Ke.   

Abstract

Hepatitis C virus screening was conducted among 8,226 residents 25-65 years of age in 4 counties of China; virus prevalence was 0.9%. A subsequent case-control study indicated blood transfusion (odds ratio [OR] 4.55), esophageal balloon examination (OR 3.78), and intravenous injection (OR 5.83) were associated with infection.

Entities:  

Mesh:

Year:  2009        PMID: 19891874      PMCID: PMC2857224          DOI: 10.3201/eid1511.090263

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


Hepatitis C virus (HCV) infection shows clear differences in prevalence among geographic regions, according to World Health Organization data (). HCV prevalence also varies over time and with behavioral changes (,). HCV prevalence in the People’s Republic of China nationwide was estimated at 3.2% in a 1992 survey (), but studies have reported regional prevalence rates ranging from 0% to 31.9% (–). In developing countries, transmission of HCV typically results primarily from iatrogenic factors, such as blood transfusion and inadequate sterilization or reuse of medical equipment (), but in industrialized countries, risk resulting from these factors has been greatly reduced (,). In an esophageal endoscopic survey (2006–2008) in Anyang, Henan Province, China, blood screening for the HCV antibody was carried out in all participants. Because HCV infection is an important public health issue, a case–control study was performed among HCV-positive case-patients with matched controls to evaluate risk factors for HCV infection in the area where the esophageal endoscopic survey was conducted.

The Study

An endoscopic survey (2006–2008) for esophageal cancer was conducted in 8 villages of 4 counties of Anyang, Henan Province, China (Figure). The villages were selected on the basis of population size, location, and village administrative capabilities. A total of 10,240 permanent residents were eligible for the survey; 8,226 (80.3%) persons 25–65 years of age (median age 42.0, M:F sex ratio 1.00:1.18) without cardiovascular or psychological diseases were interviewed and had blood drawn. A total of 74 participants were seropositive for HCV in this screening; 69 of them were enrolled in the subsequent case–control study. Each seropositive person was matched with 3 negative controls randomly selected from seronegative participants (2.5%) of the same village, gender, and age (±2 years). A questionnaire regarding lifetime risk factors for HCV infection was given to HCV seropositive case-patients and matched controls. The Institutional Review Board of the School of Oncology, Peking University, China, approved this study. Informed consent was obtained from all participants.
Figure

A) Map of eastern China showing the location of Anyang (red dot). B) Villages (red dots) targeted in the 2006–2008 hepatitis C virus prevalence study.

A) Map of eastern China showing the location of Anyang (red dot). B) Villages (red dots) targeted in the 2006–2008 hepatitis C virus prevalence study. Serum samples were separated from blood samples by centrifugation and tested for HCV in the Anyang Cancer Hospital for case-patients from Anyang, Lin, and Tangyin counties, and in the Hua County Hospital for case-patients from Hua County. ELISAs were performed to evaluate for HCV antibody (Diagnostic Kit for HCV ELISA 3.0; AutoBio Co., Zhengzhou, China). HCV-positive case-patients submitted an additional blood sample for a confirmatory HCV test in Anyang Cancer Hospital. Positivity for HCV antibody in these 2 tests was independently confirmed at Beijing Friendship Hospital by ELISA (Diagnostic Kit HCV 3.0; Abbott GmbH & Co. KG, Wiesbaden-Delkenheim, Germany). We determined the positive predictive value of the anti-HCV tests conducted in China to be 98.3% by using the testing result of the Abbott diagnostic kit as a standard. Assays were monitored with internal and external quality controls. We examined group differences using the χ2 test. Univariate and multivariate conditional logistic regression were used to identify significant factors for HCV infection. Data entry and statistical analysis were conducted using Epi Data 3.1 (www.cdc.gov/epiinfo) and SAS 9.1.3 (SAS, Cary, NC, USA); p<0.05 was considered significant. Seventy-four (0.9%) of 8,266 participants were HCV positive. Prevalence of infection varied significantly with age (p<0.001) and county of origin (p<0.001) but not with gender (Table 1). HCV prevalence was significantly higher in participants >50 years of age. Prevalence was highest in Lin County (2.8%), followed by Anyang County (0.7%), Tangyin County (0.4%), and Hua County (0.2%) (Table 1). The Lin County >50-year-old group showed an 18.25-fold higher risk for HCV infection (95% confidence interval [CI] 9.29–35.83) when compared with non–Lin County participants <50 years of age (data not shown).
Table 1

Demographic distribution and HCV infection status of participants (n = 8,226) in an esophageal endoscopic survey for HCV, Anyang, China, 2006–2008*

VariableTotal no. (%)HCV-positive, no. (%)p value
Age, y
<505,766 (70.1)37 (0.6)<0.001
>50
2,460 (29.9)
37 (1.5)

Sex
M3,782 (46.0)31 (0.8)0.479
F
4,444 (54.0)
43 (1.0)

County
Hua4,022 (48.9)7 (0.2)<0.001
Anyang838 (10.2)6 (0.7)
Lin1,980 (24.1)55 (2.8)
Tangyin1,386 (16.8)6 (0.4)

*HCV, hepatitis C virus.

*HCV, hepatitis C virus. Univariate conditional logistic regression was used to evaluate possible risk factors based on information collected from the 69 HCV-positive participants and 207 matched controls. Transfusion with blood and blood products, intravenous injection, and procedures including Caesarean section, acupuncture, gastroscopy, and esophageal balloon examination were associated with higher risk for HCV infection. No instances of hemodialysis, organ transplantation, drug use, or homosexual behavior were identified. However, when these risk factors were analyzed in a multivariate model, only blood transfusion (odds ratio [OR] 4.55, 95% CI 1.34–15.42), intravenous injection (OR 5.83, 95% CI 2.66–12.80), and esophageal balloon examination (OR 3.78, 95% CI 1.32–10.79) were significant (Table 2). A repeat analysis of participants from Lin County produced almost identical results (data not shown).
Table 2

Conditional logistic analysis of risk factors associated with hepatitis C virus infection, Anyang, China, 2006–2008*

Risk factor†ResponseTotal no.HCV negative, no. (%)HCV positive, no. (%)OR (95% CI)Adjusted OR (95% CI)
Alcohol consumption
No258195 (94.2)63 (91.3)1
Yes
18
12 (5.8)
6 (8.7)
1.71 (0.54–5.39)

Blood donation
No261199 (96.1)62 (89.9)1
Yes
15
8 (3.9)
7 (10.1)
3 (0.99–9.09)

Blood transfusion
No248197 (95.2)51 (73.9)11
Yes
28
10 (4.8)
18 (26.1)
6.32‡ (2.73–14.6)
4.55§ (1.34–15.42)
Blood products transfusion
No249191 (92.3)58 (84.1)11
Yes
27
16 (7.7)
11 (15.9)
2.49§ (1.03–6.05)
0.99 (0.28–3.5)
Intramuscular injection
No3932 (15.5)7 (10.1)1
Yes
237
175 (84.5)
62 (89.9)
1.77 (0.69–4.59)

Intravenous injection
No153136 (65.7)17 (24.6)11
Yes
123
71 (34.3)
52 (75.4)
6.75‡ (3.41–13.36)
5.83‡ (2.66–12.8)
Visited a dentist
No136103 (49.8)33 (47.8)1
Yes
140
104 (50.2)
36 (52.2)
1.09 (0.62–1.9)

Had surgery
No210171 (82.6)39 (56.5)11
Yes
66
36 (17.4)
30 (43.5)
3.78‡ (2.01–7.1)
2.29 (0.92–5.71)
Shared nail clippers
No6651 (24.6)15 (21.7)1
Yes
210
156 (75.4)
54 (78.3)
1.17 (0.62–2.23)

No. sexual partners
1262194 (93.7)68 (98.6)1
>1
14
13 (6.3)
1 (1.4)
0.21 (0.03–1.66)

Pierced ears
No173129 (62.3)44 (63.8)1
Yes
103
78 (37.7)
25 (36.2)
0.88 (0.4–1.96)

Acupuncture
No215168 (81.2)47 (68.1)1
Yes
61
39 (18.8)
22 (31.9)
2.15§ (1.11–4.13)
1.61 (0.69–3.76)
Gastroscopy
No246190 (91.8)56 (81.2)1
Yes
30
17 (8.2)
13 (18.8)
2.92§ (1.27–6.72)
2.06 (0.63–6.7)
Esophageal balloon examinationNo240190 (91.8)50 (72.5)1
Yes3617 (8.2)19 (27.5)5.95‡ (2.44–14.5)3.78§ (1.32–10.79)

*HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval.
†Blood transfusion, blood products transfusion, intravenous injection, operation, acupuncture, gastroscopy, and esophageal balloon examination were included in the multivariate model.
‡p<0.01.
§p<0.05.

*HCV, hepatitis C virus; OR, odds ratio; CI, confidence interval.
†Blood transfusion, blood products transfusion, intravenous injection, operation, acupuncture, gastroscopy, and esophageal balloon examination were included in the multivariate model.
‡p<0.01.
§p<0.05.

Conclusions

In this 2006–2008 study, overall HCV prevalence was 0.9%, with prevalence highest in the >50-year-old group of Lin County (4.7%). In a 2000 study of 55- to 84-year-old Lin County residents, the prevalence of HCV was 9.6% (). Several possible reasons could explain these differences. One is that the average age in the previous study (range 64–84 years) was greater than that in our study (range 25–65 years); older persons were more likely to be infected in both the previous study and our study. The time interval between these 2 studies might also have contributed to the change in HCV prevalence. A case–control study was performed to identify HCV infection risk factors. Blood transfusion and medical intravenous injection with reusable glass syringes and needles, which are established HCV risk factors, were associated with HCV infection (,). In addition, esophageal balloon examination, a less commonly identified route of HCV infection, also increased the risk for HCV infection. In the recent past (1980–2000), esophageal balloon examination, which was designed for early cytologic detection of esophageal lesions, was relatively common in China for diagnosis and screening of persons in high-risk populations (). In this technique, the patient swallows a balloon covered with a cotton net. The balloon is inflated within the patient’s stomach. Exfoliated esophageal cells are then scraped off the mucosa by pulling out the balloon. Bleeding of esophageal mucosa can occur. The balloon and cotton net were designed to be nonreusable. Nonetheless, on some occasions, balloons were reused after manual cleaning. This technique is no longer widely used; however, Lin County is a high-risk area for esophageal cancer. Screening for esophageal cancer using balloon examination was performed in this region before 2000. Reuse of balloons and occasional bleeding during the procedure may have caused transmission of HCV in this population. A nationwide survey for HCV infection in China was performed in 1992; prevalence was 3.1% for residents in rural areas. However, prevalence of viral infection was not consistent across regional populations, similar to what was observed in the present study (). On the basis of these regional differences in HCV distribution and the potential risk factors identified in this study, we strongly suggest that unregulated medical procedures may confer substantial risk for HCV spread. Chronic infection will develop in ≈75%–85% of persons infected with HCV, and cirrhosis of the liver will develop in up to 20% of chronically infected persons. Hepatocellular carcinoma will develop in ≈3%–4% of patients with HCV-associated cirrhosis each year (–). Given the serious social and economic effect of this HCV epidemic, strengthening administrative regulation of medical practice, especially in rural areas, and providing appropriate education to the public about HCV infection and its transmission should be given higher priority in public health policy.
  14 in total

1.  The scientific challenge of hepatitis C.

Authors:  J Cohen
Journal:  Science       Date:  1999-07-02       Impact factor: 47.728

2.  Diagnosis, management, and treatment of hepatitis C.

Authors:  Doris B Strader; Teresa Wright; David L Thomas; Leonard B Seeff
Journal:  Hepatology       Date:  2004-04       Impact factor: 17.425

3.  Studies of esophageal balloon cytology in Linxian, China.

Authors:  S M Dawsey; Q Shen; R K Nieberg; S F Liu; S A English; J Cao; B Zhou; G Q Wang; K J Lewin; F S Liu; M J Roth; P R Taylor
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1997-02       Impact factor: 4.254

4.  Persistent hyperendemicity of hepatitis C virus infection in Taiwan: the important role of iatrogenic risk factors.

Authors:  C A Sun; H C Chen; S N Lu; C J Chen; C F Lu; S L You; S H Lin
Journal:  J Med Virol       Date:  2001-09       Impact factor: 2.327

5.  The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt.

Authors:  C Frank; M K Mohamed; G T Strickland; D Lavanchy; R R Arthur; L S Magder; T El Khoby; Y Abdel-Wahab; E S Aly Ohn; W Anwar; I Sallam
Journal:  Lancet       Date:  2000-03-11       Impact factor: 79.321

Review 6.  Epidemiology of HCV infection.

Authors:  V Baldo; T Baldovin; R Trivello; A Floreani
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

7.  Prevalence of hepatitis B and C infection markers among adult women in urban and rural areas in Shaanxi Province, China.

Authors:  S Shimbo; Z W Zhang; W P Gao; Z H Hu; J B Qu; T Watanabe; H Nakatsuka; N Matsuda-Inokuchi; K Higashikawa; M Ikeda
Journal:  Southeast Asian J Trop Med Public Health       Date:  1998-06       Impact factor: 0.267

Review 8.  NIH Consensus Statement on Management of Hepatitis C: 2002.

Authors: 
Journal:  NIH Consens State Sci Statements       Date:  2002 Jun 10-12

9.  [Seroepidemiological study on hepatitis C virus infection among blood donors from various regions in China].

Authors:  S Tang
Journal:  Zhonghua Liu Xing Bing Xue Za Zhi       Date:  1993-10

10.  Hepatitis C virus infection, Linxian, China.

Authors:  Mingdong Zhang; Xiu-Di Sun; Steven D Mark; Wen Chen; Lara Wong; Sanford M Dawsey; You-Lin Qiao; Joseph F Fraumeni; Philip R Taylor; Thomas R O'Brien
Journal:  Emerg Infect Dis       Date:  2005-01       Impact factor: 6.883

View more
  12 in total

1.  Simultaneously high prevalences of hepatitis B and C virus infections in a population in Putian County, China.

Authors:  Wen-Ping Lu; Guo-Xian Lin; Shuang Shi; Jia-Hong Dong
Journal:  J Clin Microbiol       Date:  2012-03-07       Impact factor: 5.948

2.  A double robust approach to causal effects in case-control studies.

Authors:  Sherri Rose; Mark van der Laan
Journal:  Am J Epidemiol       Date:  2014-01-31       Impact factor: 4.897

Review 3.  Hepatitis C virus in the new era: perspectives in epidemiology, prevention, diagnostics and predictors of response to therapy.

Authors:  Filippo Ansaldi; Andrea Orsi; Laura Sticchi; Bianca Bruzzone; Giancarlo Icardi
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

Review 4.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

Review 5.  Acute hepatitis C: management in the rapidly evolving world of HCV.

Authors:  Suraj A Sharma; Jordan J Feld
Journal:  Curr Gastroenterol Rep       Date:  2014-02

6.  Changing pattern of clinical epidemiology on hepatitis C virus infection in southwest china.

Authors:  Zehui Yan; Ke Fan; Yuming Wang; Yi Fan; Zhaoxia Tan; Guohong Deng
Journal:  Hepat Mon       Date:  2012-03-28       Impact factor: 0.660

7.  How often are major blood-borne pathogens found in eye patients? A serosurvey at an eye hospital in Southern China.

Authors:  Fang Duan; Qiang Huang; Jingyu Liao; Dajun Pang; Xiaofeng Lin; Kaili Wu
Journal:  PLoS One       Date:  2013-09-04       Impact factor: 3.240

8.  New tools in HCV diagnosis, in light of the enhanced awareness and the new drugs for treatment: SMARTube and stimmunology.

Authors:  Svetlana Gorodin; Serhat Unal; Youchun Wang; Mikhail I Mikhaylov; Ludmila Bigbulatova; Tamar Jehuda-Cohen
Journal:  ScientificWorldJournal       Date:  2013-02-14

9.  Epidemiology of hepatitis C virus infection and risk factor analysis in the Hebei Province, China.

Authors:  Yuliang Zhao; Liping Shen; Jingchen Ma; Zhao Gao; Xu Han; Shunxiang Qi; Qi Li
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

10.  Increasing newly diagnosed rate and changing risk factors of HCV in Yanbian Prefecture, a high endemic area in China.

Authors:  Hong-Xin Piao; Ai-Ting Yang; Ya-Meng Sun; Yuan-Yuan Kong; Xiao-Ning Wu; Ying-Zhe Zhang; Bo Ding; Bao-En Wang; Ji-Dong Jia; Hong You
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.